News
ABSI
4.635
-2.83%
-0.135
Weekly Report: what happened at ABSI last week (0415-0419)?
Weekly Report · 7h ago
ENPH, OCUL and ITCI are among after hour movers
Seeking Alpha · 5d ago
Weekly Report: what happened at ABSI last week (0408-0412)?
Weekly Report · 04/15 09:13
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
NASDAQ · 04/10 15:07
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
Shares of BlackBerry Limited jumped 9% to $3.1340 on Tuesday. The company announced a collaboration with Advanced Micro Devices, Inc. The Dow Jones index fell over 200 points in today’s session. Other big U.S. Stocks were also lower.
Benzinga · 04/09 14:43
Weekly Report: what happened at ABSI last week (0401-0405)?
Weekly Report · 04/08 09:14
Weekly Report: what happened at ABSI last week (0325-0329)?
Weekly Report · 04/01 09:14
Absci Price Target Maintained With a $9.00/Share by Truist Securities
Dow Jones · 03/26 13:27
Absci Is Maintained at Buy by Truist Securities
Dow Jones · 03/26 13:27
Truist Securities Maintains Buy on Absci, Maintains $9 Price Target
Benzinga · 03/26 13:17
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), HilleVax, Inc (HLVX) and Cabaletta Bio (CABA)
TipRanks · 03/26 02:10
Absci Corp reports results for the quarter ended in December - Earnings Summary
Absci Corp reports results for the quarter ended in December. Revenue fell 78.3% to $338.00 thousand from a year ago. The company reported a quarterly loss of $23.55 million. Absci Corp shares had risen by 17.9% this quarter.
Reuters · 03/25 21:06
Analysts Are Bullish on Top Healthcare Stocks: CareCloud (CCLD), AbSci (ABSI)
TipRanks · 03/25 11:40
Weekly Report: what happened at ABSI last week (0318-0322)?
Weekly Report · 03/25 09:14
Absci Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 03/22 19:02
6 Analysts Assess Absci: What You Need To Know
Six analysts have released ratings for Absci (NASDAQ:ABSI) in the last three months. The average price target is $8.17, with a 12-month price target of $13.00. Absci Corp is the Artificial intelligence powered synthetic biology company. The company's revenue growth has lagged behind its peers in the health care sector.
Benzinga · 03/22 19:00
HC Wainwright & Co. Reiterates Buy on Absci, Maintains $7 Price Target
Benzinga · 03/22 18:52
Buy Rating Affirmed for AbSci: Promising Pipeline and Strategic Partnerships Signal Growth
TipRanks · 03/22 10:28
Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbSci (ABSI)
TipRanks · 03/21 19:10
ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q4 2023
Absci reported earnings per share of -25 cents for the fourth quarter of 2023. The company reported revenue of $338,000. This was 67.18% worse than the analyst estimate for revenue. Absci also reported results for the third quarter of 2018.
Investorplace · 03/21 18:52
More
Webull provides a variety of real-time ABSI stock news. You can receive the latest news about Absci Corp through multiple platforms. This information may help you make smarter investment decisions.
About ABSI
Absci Corporation is a generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. It has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The Company uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The Company supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. It reconstructs prevalent immune-response molecules, such as antibodies from disease tissue and identify their corresponding antigens, offering new therapeutic targets.